Mats Jerkeman
21 – 30 of 181
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2022
-
Mark
The EHA Research Roadmap: Malignant Lymphoid Diseases
(
- Contribution to journal › Article
-
Mark
Tackling Mantle Cell Lymphoma in Europe
(
- Contribution to journal › Article
-
Mark
Outcomes of relapsed/refractory diffuse large B-cell lymphoma and influence of chimaeric antigen receptor T trial eligibility criteria in second line—A population-based study of 736 patients
(
- Contribution to journal › Article
-
Mark
Impact of comorbidity in older patients with peripheral T-cell lymphoma : an international retrospective analysis of 891 patients
(
- Contribution to journal › Article
-
Mark
Molecular features encoded in the ctDNA reveal heterogeneity and predict outcome in high-risk aggressive B-cell lymphoma
(
- Contribution to journal › Article
-
Mark
Advances in immune therapies in hematological malignancies
(
- Contribution to journal › Scientific review
-
Mark
Serum proteome modulations upon treatment provides biological insight on response to treatment in relapsed mantle cell lymphoma
(
- Contribution to journal › Article
-
Mark
Idelalisib in relapsed/refractory diffuse large B-cell lymphoma : results from a Nordic Lymphoma Group phase II trial
(
- Contribution to journal › Letter
-
Mark
Survival in mantle cell lymphoma after frontline treatment with R-bendamustine, R-CHOP and the Nordic MCL2 regimen - a real world study on patients diagnosed in Sweden 2007-2017
(
- Contribution to journal › Letter
-
Mark
Clinical and biological impact of SAMHD1 expression in mantle cell lymphoma
(
- Contribution to journal › Article